Evidence record 7712 · automatically gathered

Tumor Volume Estimation and Quasi-Continuous Administration for Most Effective Bevacizumab Therapy

BACKGROUND: Bevacizumab is an exogenous inhibitor which inhibits the biological activity of human VEGF. Several studies have investigated the effectiveness of bevacizumab therapy according to different cancer types but these days there is an intense debate on its utility. We have investigated different methods to find the best tumor volume estimation since it creates the possibility for precise and effective drug administration with a much lower dose than in the protocol. MATERIALS AND METHODS:

Record details

Published: 5 November 2015
Source: OpenAlex
Category: Research
Topics: Healthcare · Finance, VC & PE · Biotech
Retrieved: 14 July 2026

source-onlyevidence status

These records share source-supplied organisations, an exact publisher byline, automatic topics or regions. The reason is shown on every link; related does not mean supporting, agreeing with or verifying this record.

How to cite this record

ethics.ai (5 November 2015), “Tumor Volume Estimation and Quasi-Continuous Administration for Most Effective Bevacizumab Therapy,” evidence record 7712, https://ethics.ai/record/7712 (originally published by OpenAlex).

JSON

Use and limitations

This page is a stable index and citation surface for a source record. ethics.ai did not author the underlying report and has not independently verified every claim. Automatic topics may be imperfect. For consequential use, quote and cite the original publisher.